KURA
Kura Oncology (KURA)
$
58About Kura Oncology (KURA)
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Details
Daily high
$18.82
Daily low
$18.10
Price at open
$18.27
52 Week High
$24.17
52 Week Low
$7.41
Market cap
1.4B
Dividend yield
0.00%
Volume
499,446
Avg. volume
487,577
P/E ratio
-8.33
Kura Oncology News
Details
Daily high
$18.82
Daily low
$18.10
Price at open
$18.27
52 Week High
$24.17
52 Week Low
$7.41
Market cap
1.4B
Dividend yield
0.00%
Volume
499,446
Avg. volume
487,577
P/E ratio
-8.33